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Figs. 1b,c). A histopathological examination revealed two
lesions, one in the ventral portion of the proximal nail fold (ar-
row) and another in the nail matrix (Fig. 1d). The former
showed nests of cells at the dermal-epidermal junction and in
the upper dermis (Fig. 1e). The nuclei were small without atypia
or prominent nucleoli. The lesion was diagnosed as compound-
type melanocytic nevus. The latter showed a lesion composed
by large abnormal cells with nuclei with atypia and prominent
nucleoli.
A 5-mmmargin excision of the nail was performed, and the
defect was covered with artificial dermis. A histopathological
examination of another longitudinal melanonychia without nail
plate dystrophy (dotted arrow in Figs. 1b,c) revealed the pres-
ence of abnormal cells with various sizes and with nuclei with
atypia and prominent nucleoli (arrow) in the basal side of the
epidermis in the nail matrix (Figs. 1f,g). Mitoses were present
(dotted arrow) (Fig. 1g).
We diagnosed the lesions of the right first toe as concomi-
tant presence of melanocytic nevus in the ventral portion of the
proximal nail fold and subungual melanoma in situ in the nail
matrix. The patient underwent skin grafting. No recurrence was
noted until March 2020.
In this case, the right first nail showed spontaneous
gradual regression of pigmentation and nail plate dystrophy
during the 3-year follow-up. Gradual color regression may
occur in longitudinal melanonychia in children.4 However, the
occurrence of nail plate dystrophy, a sign of subungual mela-
noma, prompted us to proceed with microscopic examination.
Thereafter, subungual melanoma in situ was identified in the
nail matrix.
Currently, the concept of tumor progression and evolution-
ary pathways is adapted for melanoma pathogenesis. Acral
melanomas typically begin as melanoma in situ via acral
intraepidermal atypical melanocytic proliferation (IAMP)/dyspla-
sia.5 The lesion would be under transition from acral IAMP/
dysplasia to acral melanoma in situ. We surmise that melanocy-
tic nevus and subungual melanomas in situ independently arose
in this case because the lesions are not connected and
occurred in a different part of the nail apparatus.
Subungual melanoma in situ and melanocytic nevus occa-
sionally occur in the same nail. Careful periodical examination
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Acute leukemia as the initial presentation of blastic
plasmacytoid dendritic cell neoplasm
Dear Editor,
A 90-year-old man presented with a 1-month history of fati-
gue and rapidly progressive, widespread skin lesions. Physical
examination exhibited numerous erythematous to violaceous
tumors and bruise-like patches scattered through his trunk and
limbs (Fig. 1a,b). Enlarged bilateral axillary lymph nodes were
noted.
Peripheral blood workup revealed mild macrocytic anemia
(hemoglobin 11.3 g/dl, MCV 98 fl), normal white blood cell
count (8490 9 109/l) with 27% circulating blasts, moderate
thrombocytopenia (platelets 56 9 109/l), and elevated lactate
dehydrogenase (424 U/l). Full body CT scan revealed enlarged
cervical, axillary, thoracic, iliac, and inguinal lymph nodes, and
no splenomegaly.
A skin biopsy revealed monomorphic dense dermal infiltrate
extending into the subcutis of non-epidermotropic medium-sized
cells with nuclei of irregular shape, finely dispersed chromatin,
small or absent nucleoli, and increased mitotic figures (Fig. 2a,b).
Axillary lymph node excisional biopsy revealed partial architec-
ture effacement by diffuse infiltration of medium-sized cells with
similar morphologic features. Bone marrow biopsy showed slight
dyserythropoiesis and multifocal blast infiltration. Marrow aspirate
revealed more than 10% dysgranulopoiesis and 9% blasts.
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Flow cytometric and immunohistochemical studies were
CD4, CD43, CD56, and CD123 positive in all tissue samples
including peripheral blood (Fig. 3a,b). No expression of markers
for T cells, B cells, NK cells, myeloid, and monocytic cells was
observed. A diagnosis of blastic plasmacytoid dendritic cell neo-
plasm (BPDCN) was made.
Figure 2 Histopathology features. (a) Dense dermal infiltrate
extending into the subcutis but sparing the epidermis (H&E stain;
95 magnification). (b) Detail of morphology of neoplastic cells
characterized by a monotonous proliferation of medium-sized cells
with round nuclei, finely dispersed chromatin, and small or absent
nucleoli. (H&E stain; 9400 magnification)
Figure 1 (a,b) Clinical images showing generalized erythematous
to violaceous tumors and bruise-like patches
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Azacitidine treatment was recommended because of the
age of the patient and high toxicity of conventional BPDCN
treatment. However, the patient died of pneumonia before start-
ing chemotherapy.
BPDCN is a rare hematological malignancy derived from
the precursors of myeloid-derived resting plasmacytoid dendritic
cells.1 Evolving nomenclatures have been used to describe this
entity throughout the years since its first description in 1995,
reflecting its complex pathophysiology. However, after the dis-
covery of the cell of origin and better insights on the disease’s
biology, the last and still standing classification was defined in
the 2008 World Health Organization classification of tumors of
the hematopoietic and lymphoid tissues.2
BPDCN mostly affects elderly patients and is characterized
by predominant cutaneous involvement with concomitant or
ensuing spread to the bone marrow, lymph nodes, and periph-
eral blood. Skin lesions are usually the first symptom of BPDCN
leading patients to seek medical advice, and without therapy,
they rapidly disseminate. Patients typically present with asymp-
tomatic, solitary, or multiple violaceus nodules and tumors and
bruise-like macules and patches.3
A diagnosis of BPDCN is established by histopathologic
assessment of the involved tissue coupled with germane
immunophenotypic markers including CD4, CD56, and CD123
in the absence of lineage-specific markers of lymphoid, natural
killer (NK), or myelomonocytic cells.4
The clinical course of BPDCN is aggressive, with a reported
median overall survival of 24 months.1 No standardized therapeutic
approach has been established yet, and the optimal therapy
remains to be defined. Intensive induction chemotherapy with
regimens used for acute lymphoblastic leukemia followed by
allogeneic hematopoietic stem cell transplantation is the only
potentially curative treatment option.5 However, elderly patients
with low performance status and/or significant comorbidities are
not eligible for these regimens and are usually treated with pal-
liative intent with low-dose chemotherapy or best supportive
care.1
This report portrays an exceedingly rare malignancy with
an atypical full-blown presentation with disseminated skin
lesions, acute leukemia, and extensive medullary and lymph
node disease. Based on the growing understanding of the bio-
logical landscape of the disease, new treatment options are
available and in development, and their use may challenge this
malignancy’s historical dismal prognosis.
Pedro Miguel Garrido
1*, MD








1Dermatology Department, Hospital de Santa Maria, Centro
Hospitalar Universitario Lisboa Norte (CHULN), Lisbon,
Portugal
2Hematology Department, Hospital de Santa Maria, Centro
Hospitalar Universitario Lisboa Norte (CHULN), Lisbon,
Portugal
3Faculty of Medicine, Dermatology Universitary Clinic,
University of Lisbon, Lisbon, Portugal
4Dermatology Research Unit, Instituto de Medicina Molecular
(IMM), University of Lisbon, Lisbon, Portugal
5Instituto de Higiene e Medicina Tropical (IHMT), Nova
University Lisbon, Lisbon, Portugal
*E-mail: pedro.mi.garrido@gmail.com
Conflict of interest: None.
Funding source: None.
doi: 10.1111/ijd.15166
Figure 3 Immunohistochemical studies. (a,b) Positive staining of
neoplastic cells for CD56 (CD56, 925 magnification) and CD123
(CD123, 9100 magnification)
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Pseudoxanthoma elasticum-like syndrome with
coagulation deficiency associated with carotid artery
hypoplasia and a novel gamma-glutamyl carboxylase
gene mutation
Dear Editor,
Pseudoxanthoma elasticum-like syndrome with coagulation
deficiency (PXE-like syndrome) is an autosomal recessive disor-
der caused by gamma-glutamyl carboxylase (GGCX) gene
mutations, defined by loose, redundant skin and a deficiency of
vitamin K (VK)-dependent clotting factors. Approximately 35
cases of PXE-like syndrome have been described. Clinical man-
ifestations were reported in 1971 (MacMillan and Vickers), 1989
(Rongioletti et al.) and 1996 (Le Corvaisier-Pieto et al.), while
Vanakker et al. described the ultrastructural and molecular find-
ings in 2007.1,2
We present the case of a 40-year-old male born from non-
consanguineous healthy parents. At age 18, he gradually devel-
oped skin laxity of the neck, trunk, and proximal lower
extremities. At age 40, the skin findings became worse. He also
presented with intermittent claudication. Physical examination
revealed midfacial hypoplasia, skin laxity with deep skin folds
involving the cervical, axillary, laterothoracic, and inguinal regions,
and brachyphalangy of the hands and feet (Fig. 1a–f). A skin
biopsy from the nape showed calcium deposits and degenerative
elastic fibers in the mid-dermis (Fig. 2a–c). Laboratory tests
revealed coagulation abnormalities with a prothrombin time of
14.9 seconds (normal range: 9.4–12 seconds), a prothrombin
time-international normalized ratio of 1.32 (normal: 1) and low
VK-dependent clotting factors activity with factor II 45.70% and
factor X 34.30% (normal: 50–100%). Peripapillary angioid streaks
were observed on fundoscopy. Electrocardiography and echocar-
diography were normal. Doppler ultrasound of the lower limbs
and computed tomographic angiography of the abdominal aorta
revealed calcified atheromatous plaques in the lower extremity,
internal iliac, and gluteal arteries. Computed tomographic
Figure 1 Midfacial hypoplasia (a). Skin laxity with deep cutaneous folds on the cervical, axillary, and laterothoracic regions (a–e).
Brachyphalangy of the hands (f)
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